BridgeBio Pharma (BBIO) Assets Average (2019 - 2026)

BridgeBio Pharma's Assets Average history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Assets Average rose 28.1% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 28.1% YoY), while the FY2025 annual figure was $927.7 million, up 26.58% from the prior year.
• Assets Average came in at $1.2 billion for Q1 2026 at BridgeBio Pharma, up from $967.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.2 billion in Q1 2026 to a low of $564.7 million in Q2 2023.
• A 5-year average of $804.3 million and a median of $795.5 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 32.59% in 2023 and jumped 45.55% in 2024, its largest moves.
• BridgeBio Pharma's Assets Average stood at $675.9 million in 2022, then dropped by 11.13% to $600.7 million in 2023, then soared by 31.87% to $792.2 million in 2024, then gained by 22.09% to $967.1 million in 2025, then advanced by 19.27% to $1.2 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $1.2 billion, $967.1 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison